News & Events
Get the latest news and updates from ImmunityBio
How Can ImmunityBio Help You?
Solutions for PatientsMany therapies for treating cancer and infectious disease severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.
Opportunities for Trial InvestigatorsImmunotherapies and cell therapies are key to future cancer treatments. Our investigational IL-15 superagonist, N-803, and NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.
Solutions for Research ScientistsOur NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.
ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.
EL SEGUNDO, Calif. –Sep. 21, 2020– NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6, 2020 at 12:50 PM ET. The conference presentation will be available…
NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics
Both companies agree to share equally in costs relating to COVID-19 therapeutics and vaccine candidates globally; global net profits to be shared 60%/40% in favor of the company contributing the product EL SEGUNDO and CULVER CITY, Calif., August 24, 2020– NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and…
Cord Blood Registry (CBR®) by Generate Life Sciences Partners with NantKwest to Develop Covid-19 Treatment
CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy…
ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins
Preclinical results show this next generation Adeno (hAd5) vaccine, which targets both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins, generates CD4+ and CD8+ T-cell responses, both of which can form long-term immune memory. Inclusion of nucleocapsid in this vaccine construct potentially overcomes the risk of emerging mutations in spike, which might limit…
NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
EL SEGUNDO, Calif — Jun. 29, 2020– NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock (4,811,500 shares at a price to the public of $9.50 per…
EL SEGUNDO, Calif.–Jun. 25, 2020– NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock (3,700,000 shares at a price to the public of $9.50 per share and 3,710,000 shares…
EL SEGUNDO, Calif.—Jun. 24, 2020– NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, NantKwest expects to grant the underwriters a…
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit
Download the Presentation (PDF) View the PowerPoint Presentaion
Dr. Patrick Soon-Shiong Presents NantKwest 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
San Francisco on Monday, January 7th Download the Presentation (PDF) View the PowerPoint Presentaion Listen to the Webcast
Culver City and San Diego, CA April 4, 2017 - NantKwest, Inc. (Nasdaq:NK)
NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma
CULVER CITY, Calif.--Mar. 20, 2017-- NantKwest, Inc. (Nasdaq:NK),
Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--Jan. 23, 2017-- NantKwest Inc. (Nasdaq:NK),
NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
December 19, 2016 — Culver City, California — NantKwest (Nasdaq:NK),
NEW YORK (GenomeWeb) – Consumer genomics firm Genos announced
Nantkwest Announces Landmark Study Published on high affinity haNK Cell Therapy in the Journal Oncotarget
Culver City, November 21, 2016 NantKwest Inc.
NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors
CULVER CITY, Calif.--Nov. 14, 2016-- NantKwest Inc.
Culver City, November 8, 2016 NantKwest Inc. (Nasdaq:NK),
CULVER CITY, Calif.–(BUSINESS WIRE)–Sep. 10, 2016– NantKwest, Inc (NASDAQ:NK),
Dr. Patrick Soon-Shiong is welcomed by Pope Francis
Dr. Patrick Soon-Shiong to Give Keynote Address and NantKwest to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
Culver City, May 9, 2016 -- NantKwest, Inc (Nasdaq:NK), today announced
CULVER CITY, Calif. – April 20, 2016
NantKwest to Present Data on the First Next Generation GMP-Grade NK Cell Line for Combination Immunotherapy with Rituximab, Trastuzumab, and Daratumumab at Upcoming AACR Cancer Conference
Culver City, California, April 15, 2016—NantKwest Inc.
NantBioScience and NantKwest Partner with the National Cancer Institute to Further Develop Recombinant NK Cells and Monoclonal Antibodies as Monotherapies and Combination Cancer Immunotherapies
Culver City, California, April 5, 2016—NantBioScience, Inc.,
Cancer Breakthroughs 2020 Milestone: National Breakthroughs IRB Established with Schulman IRB to Provide Central Review Services for National Immunotherapy Coalition (NIC) Clinical Trials
CULVER CITY, Calif. – March 22, 2016 – Cancer Moonshot 2020
CULVER CITY, CALIFORNIA-(BUSINESS WIRE), MARCH 4, 2016 NantKwest (Nasdaq:NK) and NantHealth
Soon-Shiong taps biotech hub for talent, biomedical manufacturing prowess By Bradley J. Fikes | 3:33 p.m. March 3, 2016
“Culver City, CA, December 22, 2015 – NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy
NantKwest Announces Presentation of Preclinical Data of HER 2. Tank at the San Antonio Breast Cancer Symposium (SABCS)
“Novel protocol combining metronomic Nant-paclitaxel with HER2-targeted natural killer cells
NantKwest, Inc (Nasdaq:NK) NantKwest today announced that the company will be presenting at the
NantKwest Continues the Strengthening of Its Leadership Team and Appoints a Seasoned Bioprocessing Manufacturing Executive
Stephen Farrand, Ph.D., former Merck executive appointed Senior Vice
--Company Adds Clinical Development, Medical Affairs and M&A Executives--
NantKwest Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
NantKwest, Inc. (formerly Conkwest, Inc.) (Nasdaq: NK), a clinical-stage immunotherapy
NantKwest, Inc. (formerly Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing
NantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing
NantKwest, Inc., a clinical-stage immunotherapy company focused on harnessing the power of the innate immune